#United States #AbbVie #North Chicago #ABBV-295 #EASD 2026

AbbVie Unveils Exciting Phase 1 Data for ABBV-295 at EASD 2026

AbbVie, a global pharmaceutical company, presented groundbreaking findings from its Phase 1 study of ABBV-295, a long-acting amylin analog, during the European Association for the Study of Diabetes (EASD) Annual Meeting held from September 28 to October 2, 2026, in Milan, Italy. This investigational therapy is poised to tackle obesity with a unique non-incretin approach, promising both safety and efficacy.

Key Highlights of the Study

The study focused on evaluating ABBV-295's pharmacokinetics, tolerability, and pharmacodynamics. Data was drawn from a cohort of 60 participants, primarily adults with a mean body mass index (BMI) below 30 kg/m², who were randomized to receive either ABBV-295 or a placebo. Participants received doses of ABBV-295 in an escalating manner: 4 mg, 6 mg, or 14 mg weekly, 14 mg every other week, or 8 mg monthly, administered over a period of 12 to 13 weeks.

Dr. Primal Kaur, AbbVie’s Senior Vice President of Global Development stated, “As the obesity treatment landscape evolves, we remain focused on differentiated approaches that help expand therapeutic options for those affected by this complex condition.” The findings indicated that ABBV-295 not only demonstrated a remarkable half-life of approximately 11 to 12 days but also supported dose-proportional increases in plasma exposure, suggesting potential for extended dosing intervals beyond the traditional weekly schedule.

Positive Outcomes

One of the most significant highlights was the dose-dependent body weight reduction observed during the trial. Participants on ABBV-295 experienced weight losses ranging from 7.8% to 9.8% depending on the dosing regimen, contrasting sharply with a negligible improvement in the placebo group. This performance signifies ABBV-295's potential as a new player in chronic weight management therapies.

Moreover, the favorable tolerability profile noted in the study adds to its viability. The majority of gastrointestinal (GI) adverse events reported were mild and transient, primarily occurring within the first six weeks of treatment. Notably, nausea was experienced by 33.3% of ABBV-295 recipients, whereas only 20.0% of placebo participants reported similar symptoms. Importantly, there were no reports of severe GI issues.

Safety and Tolerability Profile

The analysis also highlighted that there were no serious treatment-emergent adverse events (TEAEs) among ABBV-295 users, further establishing its safety profile. Commonly reported mild AEs included decreased appetite and fatigue. This aspect is crucial for maintaining patient adherence to treatment as managing a chronic disease like obesity often entails long-term medication usage.

Dr. Juan Pablo Frías, the Medical Director and Primary Investigator at the Los Angeles Institute for Metabolic Research, emphasized, “These results indicate that ABBV-295 offers a robust weight loss solution with the added benefit of extended dosing intervals.” He further indicated the necessity of considering patients' practical realities regarding treatment frequency and tolerability in their management plans.

• ---

Conclusion

As AbbVie gears up for Phase 2 development, the advancements made with ABBV-295 signal a promising horizon for obesity treatment modalities. By targeting the amylin pathway, ABBV-295 stands apart from existing therapies, potentially offering a new alternative that could meet the diverse needs of individuals grappling with obesity. The forthcoming phases of clinical trials will aim to further clarify the benefits of this innovative therapy and its role in the broader landscape of obesity management.

For additional details on this intriguing therapy and ongoing developments, stay tuned to updates from AbbVie and clinical trial registries.

• ---

ABBV-295 remains a work in progress, and its efficacy and safety await further validation through ongoing studies.